DEBASISH TRIPATHY to Treatment Outcome
This is a "connection" page, showing publications DEBASISH TRIPATHY has written about Treatment Outcome.
Connection Strength
0.380
-
Biologically targeted therapy: as good as advertized? Clin Breast Cancer. 2003 Jun; 4(2):89.
Score: 0.049
-
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clin Cancer Res. 2017 07 01; 23(13):3251-3262.
Score: 0.032
-
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):725-34.
Score: 0.026
-
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. Curr Opin Obstet Gynecol. 2014 Feb; 26(1):27-33.
Score: 0.026
-
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10.
Score: 0.025
-
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
Score: 0.023
-
Are we hitting the right combination for hormonally sensitive breast cancer? J Clin Oncol. 2009 Jun 01; 27(16):2580-2.
Score: 0.019
-
Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med. 2005; 56:103-16.
Score: 0.014
-
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004 Oct; 5(4):293-8.
Score: 0.014
-
Clinical testing of supplementation therapy in early stage breast cancer: pitfalls and opportunities. Integr Cancer Ther. 2003 Jun; 2(2):160-2.
Score: 0.012
-
Multidisciplinary care for breast cancer: barriers and solutions. Breast J. 2003 Jan-Feb; 9(1):60-3.
Score: 0.012
-
Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol. 2002 Dec; 29(6):563-74.
Score: 0.012
-
Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer. 2002 May; 3 Suppl 1:8-11.
Score: 0.011
-
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
Score: 0.010
-
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9.
Score: 0.008
-
Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23.
Score: 0.007
-
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.
Score: 0.007
-
The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. Ann Oncol. 2004 Oct; 15(10):1574; author reply 1574-5.
Score: 0.007
-
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27; 110(11):2756-64.
Score: 0.007
-
Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. BMC Cancer. 2014 Apr 03; 14:238.
Score: 0.007
-
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70.
Score: 0.006
-
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003 Sep; 14(9):1399-405.
Score: 0.006
-
Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study. J Magn Reson Imaging. 2013 May; 37(5):1083-92.
Score: 0.006
-
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012 Oct; 135(3):875-83.
Score: 0.006
-
Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain. 2011 Apr; 12(4):495-507.
Score: 0.005
-
Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7.
Score: 0.004
-
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72.
Score: 0.003
-
Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004 May 01; 22(9):1713-20.
Score: 0.003
-
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
Score: 0.003
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
Score: 0.003
-
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59.
Score: 0.003
-
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
Score: 0.003
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.003